About: Recombinant Receptor Binding Domain Protein Induces Partial Protective Immunity in Rhesus Macaques Against Middle East Respiratory Syndrome Coronavirus Challenge()

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Recombinant Receptor Binding Domain Protein Induces Partial Protective Immunity in Rhesus Macaques Against Middle East Respiratory Syndrome Coronavirus Challenge() Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Recombinant Receptor Binding Domain Protein Induces Partial Protective Immunity in Rhesus Macaques Against Middle East Respiratory Syndrome Coronavirus Challenge()
Creator	Lu, Guangwen Deng, Yao Tan, Wenjie Wang, Wen Qin, Chuan Lan, Jiaming Gao, George Yao, Yanfeng Wei, Qiang Bao, Linlin Chen, Hong Deng, Wei
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: Development an effective vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) is urgent and limited information is available on vaccination in nonhuman primate (NHP) model. We herein report of evaluating a recombinant receptor-binding domain (rRBD) protein vaccine in a rhesus macaque model. METHODS: Nine monkeys were randomly assigned to high-dose, low-dose and mock groups,which were immunized with different doses of rRBD plus alum adjuvant or adjuvant alone at different time points (0, 8, 25 weeks). Immunological analysis was conducted after each immunisation. Monkeys were challenged with MERS-CoV at 14 days after the final immunisation followed by observation for clinical signs and chest X-rays. Nasal, oropharyngeal and rectal swabs were also collected for analyses. Monkeys were euthanized 3 days after challenge and multiple specimens from tissues were collected for pathological, virological and immunological tests. CONCLUSION: Robust and sustained immunological responses (including neutralisation antibody) were elicited by the rRBD vaccination. Besides, rRBD vaccination alleviated pneumonia with evidence of reduced tissue impairment and clinical manifestation in monkeys. Furthermore, the rRBD vaccine decreased viral load of lung, trachea and oropharyngeal swabs of monkeys. These data in NHP paves a way for further development of an effective human vaccine against MERS-CoV infection.
has issue date	2015-08-18(xsd:dateTime)
bibo:doi	10.1016/j.ebiom.2015.08.031
bibo:pmid	26629538
has license	cc-by-nc-nd
sha1sum (hex)	cd20636717b2150e71b69c9d62945a8f3a49b809
schema:url	https://doi.org/10.1016/j.ebiom.2015.08.031
resource representing a document's title	Recombinant Receptor Binding Domain Protein Induces Partial Protective Immunity in Rhesus Macaques Against Middle East Respiratory Syndrome Coronavirus Challenge()
has PubMed Central identifier	PMC4634622
has PubMed identifier	26629538
schema:publication	EBioMedicine
resource representing a document's body	covid:cd20636717b2150e71b69c9d62945a8f3a49b809#body_text
is schema:about of	named entity '25 WEEKS' named entity 'REDUCED' named entity 'GROUPS' named entity 'DIFFERENT' named entity 'TIME' named entity 'MOCK' named entity 'ANTIBODY' named entity 'PROTEIN ' named entity 'MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS' named entity 'LIMITED' named entity 'RHESUS MACAQUE' named entity 'BACKGROUND' named entity 'WAY' named entity 'INFECTION' named entity 'EVIDENCE OF' named entity 'THESE' named entity 'HIGH-DOSE' named entity 'COLLECTED' named entity 'METHODS' named entity 'NHP' named entity 'NONHUMAN PRIMATE' named entity 'ANALYSIS' named entity 'MONKEYS' named entity 'VIROLOGICAL' named entity 'OROPHARYNGEAL' named entity 'collected' named entity 'viral load' named entity 'Conclusion' named entity 'reduced' named entity 'human' named entity 'vaccine' named entity 'conducted' named entity 'limited' named entity 'monkeys' named entity 'tests' named entity 'licenses' named entity 'Partial' named entity 'Macaques' named entity 'PARTIAL' named entity 'LICENSE' covid:arg/cd20636717b2150e71b69c9d62945a8f3a49b809 named entity 'PROTEIN ' named entity 'RECOMBINANT' named entity 'RHESUS MACAQUES' named entity 'HUMAN' named entity 'ADJUVANT' named entity 'CLINICAL MANIFESTATION' named entity 'ORG' named entity 'PROTECTIVE IMMUNITY' named entity 'NASAL' named entity 'PNEUMONIA' named entity 'VIRAL LOAD' named entity 'DOMAIN' named entity 'RECOMBINANT' named entity 'EFFECTIVE' named entity 'URGENT' named entity 'IMPAIRMENT' named entity 'CONCLUSION' named entity 'VACCINE' named entity 'CHALLENGE' named entity 'MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS' named entity 'DOMAIN' named entity 'NC-' named entity 'DATA' named entity 'DEVELOPMENT' named entity 'X-RAYS' named entity 'FOLLOWED BY' named entity 'EUTHANIZED' named entity 'ELICITED BY' named entity 'ASSIGNED'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software